HRA000906
Title:
Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
Release date:
2021-11-03
Description:
In prospective clinical study (ChiCTR1900020990, China), personalized neoantigen vaccine was designed and immunized for 10 HCC patients with high risk of postoperative recurrence in a prime boost schedule. No obvious adverse events were observed during neoantigen vaccinations. After vaccination, 70% patients showed neoantigen specific immune response, and have significantly longer RFS than other 3 patients without neoantigen specific immune response or 14 propensity scores matching patients without neoantigen vaccination. Meanwhile, tumor immunological microenvironment could be turned into hot after receiving neoantigen vaccination. Moreover, tracking personalized neoantigen mutations in ctDNA could provide real-time evaluation of clinical response and reflect potential tumor immune escape in HCC patients during neoantigen vaccination and follow up.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
hepatocellular carcinoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
CAS_HCC
Contact person:
Cai Zhixiong
Email:
caizhixiong1985@163.com
Description:
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province
Individuals & samples
Submitter:   Liu Xiaolong / xiaoloong.liu@gmail.com
Organization:   Mengchao Hepatobiliary Hospital of Fujian Medical University
Submission date:   2021-05-31
Requests:   2